A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (Start II)

AIDS

Volumn 14, Issue 11, 2000, Pages 1601-1610

  Eron Jr , Joseph J ^a,m   Murphy, Robert L ^b   Peterson, Dolores ^c   Pottage, John ^d   Parenti, David M ^e   Jemsek, Joseph ^f   Swindells, Susan ^g   Sepulveda, Gladys ^h   Bellos, Nicholaos ⁱ   Rashbaum, Bruce C ^j   Esinhart, Jim ^k   Schoellkopf, Nancy ^k   Grosso, Robert ^l   Stevens, Michael ^l  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^f Nalle Clinic   (United States)

^g UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^h PONCE HEALTH SCIENCES UNIVERSITY   (Puerto Rico)

ⁱ Southwest Infectious Disease Associates   (United States)

^j Physician's Home Service   (United States)

^k PharmaResearch Corporation   (United States)

^l BRISTOL MYERS SQUIBB   (United States)

^m UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

Combination antiretroviral therapy; Didanosine; Indinavir; Randomized trial; Stavudine; Zidovudine lamivudine

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINUSITIS; TASTE DISORDER; TREATMENT OUTCOME; VIREMIA;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THYMIDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 0033821270     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00016     Document Type: Article

References (36)

1. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
2. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
3. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogs in human immunodeficiency virus infected persons with CD4 counts less than or equal to 200 per cubic millimeter
4. Report of the N.I.H. panel to define principles of therapy in HIV infection
5. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Patrol
6. Guidelines for the use of antiretroviral therapy in HIV-infected adults and adolescents
7. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter
8. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection
9. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy
10. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: A randomized controlled comparison with zidovudine monotherapy
11. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 Week follow-up
12. Zidovudine: Five years later
13. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
14. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
15. Stavudine plus lamivudine in advanced human immunodeficiency virus disease: A short-term pilot study
16. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
17. Lamivudine in combination with zidovudine, stavudine or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
18. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients
19. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patters of pol gene mutations
20. Susceptibilities of HIV-1 isolates derived from patients treated with didanosine and stavudine in combination
21. A family of insertion mutations between condons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
22. Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma
23. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS. Italy, The Netherlands, Canada and Australia Study
24. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
25. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
26. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
27. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
28. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
29. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
30. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine